Insider · CIK 0001856369

Gibson Christopher

Reports to the SEC for 2 companies · SALT LAKE CITY, UT

sec.gov

Transactions

Companies

Filings

CIK

0001856369

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-05	RXRXRECURSION PHARMACEUTICALS, INC.C Conversion	Director	CConversion	+40K sh	—	—	923,735
2026-06-05	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Director	SSale	−40K sh	$3.62	−$145K	883,735
2026-06-05	RXRXRECURSION PHARMACEUTICALS, INC. · Class B Common StockC Conversion	Director	CConversion	−40K sh	—	—	4,263,334
2026-06-03	PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC. · Stock Option (right to buy)A Award	Director	AAward	+74.5K sh	—	—	74,497
2026-05-22	RXRXRECURSION PHARMACEUTICALS, INC.C Conversion	Director	CConversion	+40K sh	—	—	923,735
2026-05-22	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Director	SSale	−40K sh	$3.08	−$123K	883,735
2026-05-22	RXRXRECURSION PHARMACEUTICALS, INC. · Class B Common StockC Conversion	Director	CConversion	−40K sh	—	—	4,303,334
2026-05-15	RXRXRECURSION PHARMACEUTICALS, INC.F Tax Payment	Director	FTax Payment	−22.8K sh	$3.04	−$69.4K	883,735
2026-05-07	RXRXRECURSION PHARMACEUTICALS, INC.C Conversion	Director	CConversion	+60K sh	—	—	966,556
2026-05-07	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Director	SSale	−40K sh	$3.37	−$135K	926,556
2026-05-07	RXRXRECURSION PHARMACEUTICALS, INC.G Gift	Director	GGift	−20K sh	—	—	906,556
2026-05-07	RXRXRECURSION PHARMACEUTICALS, INC. · Class B Common StockC Conversion	Director	CConversion	−60K sh	—	—	4,343,334
2026-04-22	RXRXRECURSION PHARMACEUTICALS, INC.C Conversion	Director	CConversion	+40K sh	—	—	946,556
2026-04-22	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Director	SSale	−40K sh	$3.61	−$144K	906,556
2026-04-22	RXRXRECURSION PHARMACEUTICALS, INC. · Class B Common StockC Conversion	Director	CConversion	−40K sh	—	—	4,403,334
2026-04-08	PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC.A Award	Director	AAward	+57.5K sh	—	—	111,386
2026-04-08	PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC. · Stock Option (right to buy)A Award	Director	AAward	+77.8K sh	—	—	77,842
2026-04-07	RXRXRECURSION PHARMACEUTICALS, INC.C Conversion	Director	CConversion	+40K sh	—	—	946,556
2026-04-07	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Director	SSale	−40K sh	$3.10	−$124K	906,556
2026-04-07	RXRXRECURSION PHARMACEUTICALS, INC. · Class B Common StockC Conversion	Director	CConversion	−40K sh	—	—	4,443,334
2026-03-23	RXRXRECURSION PHARMACEUTICALS, INC.C Conversion	Director	CConversion	+40K sh	—	—	946,556
2026-03-23	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Director	SSale	−40K sh	$3.25	−$130K	906,556
2026-03-23	RXRXRECURSION PHARMACEUTICALS, INC. · Class B Common StockC Conversion	Director	CConversion	−40K sh	—	—	4,483,334
2026-03-09	RXRXRECURSION PHARMACEUTICALS, INC.C Conversion	Director	CConversion	+20K sh	—	—	926,556
2026-03-09	RXRXRECURSION PHARMACEUTICALS, INC.G Gift	Director	GGift	−20K sh	—	—	906,556
2026-03-09	RXRXRECURSION PHARMACEUTICALS, INC. · Class B Common StockC Conversion	Director	CConversion	−20K sh	—	—	4,523,334
2026-03-03	PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC.A Award	Director	AAward	+53.9K sh	—	—	53,913
2026-03-03	PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC. · Stock Option (right to buy)A Award	Director	AAward	+73.1K sh	—	—	73,087
2026-02-19	RXRXRECURSION PHARMACEUTICALS, INC.C Conversion	Director	CConversion	+40K sh	—	—	946,556
2026-02-19	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Director	SSale	−40K sh	$3.46	−$138K	906,556
2026-02-19	RXRXRECURSION PHARMACEUTICALS, INC. · Class B Common StockC Conversion	Director	CConversion	−40K sh	—	—	4,543,334
2026-02-17	RXRXRECURSION PHARMACEUTICALS, INC.F Tax Payment	Director	FTax Payment	−27.3K sh	$3.49	−$95.2K	906,556
2026-02-06	RXRXRECURSION PHARMACEUTICALS, INC.A Award	Director	AAward	+30.3K sh	—	—	944,185
2026-02-06	RXRXRECURSION PHARMACEUTICALS, INC.F Tax Payment	Director	FTax Payment	−10.4K sh	$3.56	−$36.9K	933,821
2026-02-04	RXRXRECURSION PHARMACEUTICALS, INC.C Conversion	Director	CConversion	+40K sh	—	—	953,839
2026-02-04	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Director	SSale	−40K sh	$4.12	−$165K	913,839
2026-02-04	RXRXRECURSION PHARMACEUTICALS, INC. · Class B Common StockC Conversion	Director	CConversion	−40K sh	—	—	4,583,334
2026-01-20	RXRXRECURSION PHARMACEUTICALS, INC.C Conversion	Director	CConversion	+40K sh	—	—	953,839
2026-01-20	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Director	SSale	−40K sh	$4.47	−$179K	913,839
2026-01-20	RXRXRECURSION PHARMACEUTICALS, INC. · Class B Common StockC Conversion	Director	CConversion	−40K sh	—	—	4,623,334
2026-01-05	RXRXRECURSION PHARMACEUTICALS, INC.C Conversion	Director	CConversion	+60K sh	—	—	973,839
2026-01-05	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Director	SSale	−40K sh	$4.25	−$170K	933,839
2026-01-05	RXRXRECURSION PHARMACEUTICALS, INC.G Gift	Director	GGift	−20K sh	—	—	913,839
2026-01-05	RXRXRECURSION PHARMACEUTICALS, INC. · Class B Common StockC Conversion	Director	CConversion	−60K sh	—	—	4,663,334
2025-12-19	RXRXRECURSION PHARMACEUTICALS, INC.C Conversion	Director	CConversion	+40K sh	—	—	953,839
2025-12-19	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Director	SSale	−40K sh	$4.50	−$180K	913,839
2025-12-19	RXRXRECURSION PHARMACEUTICALS, INC. · Class B Common StockC Conversion	Director	CConversion	−40K sh	—	—	4,723,334
2025-12-04	RXRXRECURSION PHARMACEUTICALS, INC.C Conversion	Director	CConversion	+60K sh	—	—	973,839
2025-12-04	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Director	SSale	−40K sh	$4.63	−$185K	933,839
2025-12-04	RXRXRECURSION PHARMACEUTICALS, INC.G Gift	Director	GGift	−20K sh	—	—	913,839

Recent filings

Accepted (ET)
Jun 54
Gibson Christopher0001856369-26-000023
SEC(opens sec.gov)
Jun 44
Gibson Christopher0001299130-26-000106
SEC(opens sec.gov)
May 274
Gibson Christopher0001856369-26-000019
SEC(opens sec.gov)
May 194
Gibson Christopher0001856369-26-000017
SEC(opens sec.gov)
May 84
Gibson Christopher0001856369-26-000015
SEC(opens sec.gov)
Apr 244
Gibson Christopher0001856369-26-000013
SEC(opens sec.gov)
Apr 104
Gibson Christopher0001856369-26-000010
SEC(opens sec.gov)
Apr 84
Gibson Christopher0001856369-26-000008
SEC(opens sec.gov)

Companies

Address

C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET

SALT LAKE CITY, UT, 84101